Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.

The key secondary end point of percent change in htTKV from baseline to month 12 showed that participants aged 12–17 years at baseline experienced a lower rate of kidney volume growth with tolvaptan (2.6%) than placebo (5.8%), although the difference did not reach statistical significance.

also in 111,027 other papers